Literature DB >> 12909735

NF-kappaB in pancreatic cancer.

Guido M Sclabas1, Shuichi Fujioka, Christian Schmidt, Douglas B Evans, Paul J Chiao.   

Abstract

Although the genetic profile of pancreatic cancer is emerging as a result of much research, the role of specific genetic alterations that initiate tumorigenesis and produce its cardinal clinical features of locally aggressive growth, metastasis, and chemotherapy resistance remains unresolved. Recently, a number of studies have shown that the inhibition of constitutive NF-kappaB activation, one of the frequent molecular alterations in pancreatic cancer, inhibits tumorigenesis and metastasis. It also sensitizes pancreatic cancer cell lines to anticancer agent-induced apoptosis. Therefore because of the crucial role of NF-kappaB in pancreatic cancer, it is a potential target for developing novel therapeutic strategies for the disease. In vivo and in vitro models that mimic the tumorigenic phenotypes in the appropriate histological and molecular concert would be very useful for confirming the suspected role of the pancreatic cancer signature genetic lesions and better understanding the molecular basis of this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12909735     DOI: 10.1385/IJGC:33:1:15

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  161 in total

1.  [Transcription factor NF-kappa B/RelA are constitutively activated and localized in the cell nuclei of E1A + cHa-Ras transformants].

Authors:  Z A Darieva; V A Pospelov; T V Pospelova
Journal:  Tsitologiia       Date:  1999

Review 2.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 3.  NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.

Authors:  M J Lenardo; D Baltimore
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

4.  IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK.

Authors:  J D Woronicz; X Gao; Z Cao; M Rothe; D V Goeddel
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

5.  Structure of an IkappaBalpha/NF-kappaB complex.

Authors:  M D Jacobs; S C Harrison
Journal:  Cell       Date:  1998-12-11       Impact factor: 41.582

6.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

7.  Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation.

Authors:  Pei Yen Yeh; Shuang-En Chuang; Kun-Huei Yeh; Ying Chyi Song; Chee-Kwee Ea; Ann-Lii Cheng
Journal:  Biochem Pharmacol       Date:  2002-04-15       Impact factor: 5.858

8.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

9.  TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway.

Authors:  Giichi Takaesu; Rama M Surabhi; Kyu-Jin Park; Jun Ninomiya-Tsuji; Kunihiro Matsumoto; Richard B Gaynor
Journal:  J Mol Biol       Date:  2003-02-07       Impact factor: 5.469

10.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

View more
  26 in total

Review 1.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Molecular predictors of gemcitabine response in pancreatic cancer.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2011-11-15

Review 3.  Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.

Authors:  Tadashi Uwagawa; Katsuhiko Yanaga
Journal:  Surg Today       Date:  2015-02-12       Impact factor: 2.549

4.  Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.

Authors:  Xiaodong Tian; Kun Hao; Changfu Qin; Kun Xie; Xuehai Xie; Yinmo Yang
Journal:  Dig Dis Sci       Date:  2013-04-16       Impact factor: 3.199

5.  Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells.

Authors:  Navdeep Chehl; Galina Chipitsyna; Qiaoke Gong; Charles J Yeo; Hwyda A Arafat
Journal:  HPB (Oxford)       Date:  2009-08       Impact factor: 3.647

6.  TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer.

Authors:  Zhiwei Wang; Wen Song; Amro Aboukameel; Mussop Mohammad; Guoping Wang; Sanjeev Banerjee; Dejuan Kong; Shaomeng Wang; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Int J Cancer       Date:  2008-08-15       Impact factor: 7.396

Review 7.  Genetically engineered mouse models of pancreatic adenocarcinoma.

Authors:  Carmen Guerra; Mariano Barbacid
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

8.  Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells.

Authors:  Catherine E Wharry; Kathleen M Haines; Richard G Carroll; Michael J May
Journal:  Cancer Biol Ther       Date:  2009-08-08       Impact factor: 4.742

9.  Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Zhiwei Wang; Dejuan Kong; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

10.  Impact of Osteopenia on Oncologic Outcomes After Curative Resection for Pancreatic Cancer.

Authors:  Takashi Motomura; Hideaki Uchiyama; Tomohiro Iguchi; Mizuki Ninomiya; Rintaro Yoshida; Takuya Honboh; Noriaki Sadanaga; Tetsuro Akashi; Hiroshi Matsuura
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.